Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio

Reuters05-21

Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio

Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE® alongside its flagship antibiotic, NUZYRA®. Optinose shareholders received $9 per share in cash and contingent value rights (CVRs) for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptiNose Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051326), on May 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2537795938?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537795938","market":"nz","top_or_hot":-1,"title":"Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE® alongside its flagship antibiotic, NUZYRA®. Optinose shareholders received $9 per share in cash and contingent value rights (CVRs) for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptiNose Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051326), on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParatek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE® alongside its flagship antibiotic, NUZYRA®. Optinose shareholders received $9 per share in cash and contingent value rights (CVRs) for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptiNose Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051326), on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPTN","symbol_name":"Optinose Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL2ZdkkJ:1","article_id":"2537795938","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537795938","pubTimestamp":1747830998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE alongside its flagship antibiotic, NUZYRA. Optinose shareholders received $9 per share in cash and contingent value rights  for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPTN":"Optinose Inc.","BK4007":"制药"},"translate_title":"Paratek Pharmaceuticals完成对Optinose的收购，扩大专业疗法产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPTN":0.9},"content_text":"Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio\n    \n\n        Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE® alongside its flagship antibiotic, NUZYRA®. Optinose shareholders received $9 per share in cash and contingent value rights (CVRs) for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptiNose Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051326), on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537795938","isCrawlerRequest":true}